AMRN

Vascepa

Cardiovascular Disease / Triglycerides

Approved (litigation)

Exp Date

ANDA litigation (Filing Appeal/ Hearing in Q3 or Q4 2020)

Amp Volatility Score

41%

Catalyst Info & Data Links

Catalyst Events:


Related Links


Prior Data:

  • District Court ruled against AMRN on March 30, 2020 on invalidity, ruling the asserted patents invalid as obvious. See our article here: https://bit.ly/2UvY1Hq


Prior Data Links:

  1. AMRN comments on court ruling PR

  2. Vascepa Label

  3. Reduce-It MACE trial results


HC updated 5/21/20


Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

PROUDLY CREATED WITH WIX.COM

  • Twitter Social Icon
  • LinkedIn Social Icon